Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Changes in Pennsaid marketing and distribution agreements

June 27, 2002

More on the gastrointestinal safety of the specific COX-2 inhibitor valdecoxib

June 26, 2002

Good safety and efficacy profiles reported for adalimumab in Stockholm

June 26, 2002

IL-6 production inhibitors identified at Taisho and Sagami

June 26, 2002

Orally available prodrugs of MMP inhibitors presented by Sumitomo

June 26, 2002

Genelabs permitted to seek E.U. approval for Aslera under centralized procedure

June 21, 2002

Potent inhibitors of IL-12 production and potential therapeutic applications

June 20, 2002

A wealth of data on lumiracoxib presented at the EULAR congress

June 20, 2002

Novel antiinflammatory agents from Celgene act by inhibiting transcriptional activation in T-cells

June 20, 2002

Novel COX-2 inhibitors in early development at GSK

June 20, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...